Phase 3 Pulmonary Hypertension Trial, Recruiting NCT04062565 Sponsor: University of Arizona Condition: Pulmonary Hypertension
Back to Pulmonary Hypertension

Phase 3 Pulmonary Hypertension Trial, Recruiting

NCT04062565
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with a specific type of pulmonary arterial hypertension (high blood pressure in the lungs) classified as WHO Category I
  • Testing of your heart (via a procedure called right heart catheterization) has shown that the pressure in your pulmonary artery is high and that the pressure on the left side of your heart is normal
  • A pulmonary hypertension specialist has decided you need a specific medication given through a vein or under the skin (parenteral treprostinil)

Who may not be able to join:

  • Your general blood pressure is very low (below 60 mmHg) or you need medications to keep your blood pressure up
  • Your doctors expect you will soon need a heart-lung support machine (such as ECMO or a right heart assist device) or a lung transplant within the next 3 months
  • Your heart's left pumping chamber is not working well enough, or you have heart failure of a certain type, or you have moderate-to-severe problems with your aortic or mitral heart valves
  • You have severe lung disease that significantly limits how much air you can breathe in or out (confirm with trial site)
  • You have had a blood clot in your lungs (pulmonary embolism) in the last 3 months, or you have evidence of long-term blood clots in your lungs
  • You have a medical reason why you cannot safely have a right heart catheterization procedure
  • You have taken any medications that affect the blood vessels in your lungs in the last 12 weeks
  • Your pulmonary hypertension involves the veins or small blood vessels of the lungs in a specific way, or you have certain related rare lung conditions (confirm with trial site)
  • Your pulmonary hypertension belongs to WHO groups 2 through 5 (meaning it is caused by other conditions such as heart disease, lung disease, blood clots, or other disorders)
  • You have moderate or severe liver disease (classified as Child-Pugh Class B or C)
  • Your kidneys are not working well enough (kidney filtration rate below 30 mL/min)
  • Certain liver enzyme levels in your blood (AST and/or ALT) are too high
  • Your hemoglobin (a measure of red blood cells) is significantly below the normal range
  • You have a physical condition (other than breathlessness) that would make it hard to take part in the study
  • You are currently pregnant or breastfeeding
  • If you are a woman who could become pregnant, you are not willing or able to either avoid sexual intercourse or use two reliable forms of contraception during the study and for at least 30 days after finishing the study medication
  • You have another serious illness where doctors expect you may not survive beyond 12 months
  • Your body weight is below 40 kg (about 88 lbs) or above 150 kg (about 330 lbs)
  • You have any other condition that would make it difficult to follow the study rules or take the medication as required
  • You are currently taking certain medications that could interact with the study drugs, including some antifungal, antibiotic, or HIV medications, or theophylline (confirm full list with trial site)
  • You have taken any nitrate medications (such as those used for chest pain) within the 4 weeks before joining the study
  • You have a known allergy or sensitivity to medications in the same family as the study drugs
  • You have been treated with, or are planned to receive, another experimental drug within 1 month before joining the study
  • You have coughed up blood in the last 6 months, or have a history of severe episodes of coughing up blood that needed a medical procedure to stop it

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Franz Rischard, DO, University of Arizona

Phone: 520-626-8305

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
University of Arizona
Registry
ClinicalTrials.gov
Start date
25 March 2019
Est. completion
31 December 2025

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in stroke volume/end systolic volume (SV/ESV)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov